Healthequity (HQY) Research & Development (2013 - 2026)

Healthequity's Research & Development history runs 14 years deep, the most recent figure standing at $26.8 million for Q2 2026.

• On a quarterly basis, Research & Development rose 3.27% year-over-year to $26.8 million in Q2 2026; TTM through Apr 2026 was $308.2 million, a 10.26% increase from a year earlier, with the FY2026 full-year figure at $262.5 million, up 9.6% from the prior year.
• Research & Development retreated to $26.8 million in Q2 2026 per HQY's latest filing, from $192.2 million in the prior quarter.
• Across five years, Research & Development topped out at $192.2 million in Q1 2026 and bottomed at $15.8 million in Q3 2022.
• The 5-year median for Research & Development is $26.4 million (2025), against an average of $58.9 million.
• Across the five-year window, Research & Development tumbled 85.7% in 2024 and jumped 735.93% in 2025, its largest moves.
• Year by year, Research & Development stood at $17.2 million in 2022, then climbed by 13.98% to $19.7 million in 2023, then surged by 206.21% to $60.2 million in 2024, then sank by 59.44% to $24.4 million in 2025, then gained by 9.92% to $26.8 million in 2026.
• Per Business Quant, the three latest HQY Research & Development figures stand at $26.8 million (Q2 2026), $192.2 million (Q1 2026), and $24.4 million (Q4 2025).